Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Akhteruzzaman Molla, Marina Korneyeva, Qing Gao et al. · Nature Medicine · 1996 · 768 citations

Life Sciences, Genetics, Molecular Biology +14

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Hing L. Sham, Dale J. Kempf, Akhteruzammen Molla et al. · Antimicrobial Agents and Chemotherapy · 1998 · 470 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Dale J. Kempf, Kennan C. Marsh, Gondi Kumar et al. · Antimicrobial Agents and Chemotherapy · 1997 · 420 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

Robert L. Murphy, Scott Brun, Charles B. Hicks et al. · AIDS · 2001 · 239 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Dale J. Kempf, Jeffrey D. Isaacson, Martin King et al. · Journal of Virology · 2001 · 233 citations

Life Sciences, Genetics, Infectious Diseases +17